Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery
International Journal of Molecular Sciences · 19.06.2026 · 27 (12) · 5553
DOI: 10.3390/ijms27125553 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.06.2026. Verfasst von Hugo Ramos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Neuroprotective Agents, Ophthalmic Solutions, Neuroprotection. Die Arbeit nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Economy and Competitiveness, Ministry of Science and Information, Institute of Health Carlos III.
Abstract (Originalsprache)
Diabetic retinal disease (DRD) has classically been defined as a microvascular complication of diabetes; however, the recent evidence highlighted the key role of neuronal degeneration during the earliest stages of its pathogenesis. Therefore, neuroprotection has emerged as a promising therapeutic strategy to prevent disease progression. Topical administration via eyedrops represents a non-invasive approach to deliver neuroprotective agents directly to the retina. This review summarizes the current advances in the field of neuroprotective therapies against early DRD with a special focus on topical delivery, including preclinical and clinical evidence, while discussing the relevance of the transscleral route of absorption in all of them. In this review, the most promising neuroprotective compounds under development will be discussed, highlighting the opportunity that they represent for treating early stages of DRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.
- Center for Networked Biomedical Research of Diabetes and Associated Metabolic Diseases (CIBERDEM), Carlos III Health Institute (ICSIII), 28029 Madrid, Spain.
- Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain.
ORCID-Profile: Hugo Ramos, Olga Simó-Servat, Cristina Hernández, Rafael Simó
Förderung
- Ministry of Economy and Competitiveness
- Ministry of Science and Information
- Institute of Health Carlos III
- Universidad Técnica Estatal de Quevedo
Zitieren
APA
Ramos, H., Simó-Servat, O., Hernández, C., & Simó, R. (2026). Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery. International Journal of Molecular Sciences, 27(12), 5553. https://doi.org/10.3390/ijms27125553
Vancouver
Ramos H, Simó-Servat O, Hernández C, Simó R. Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery. International Journal of Molecular Sciences. 2026;27(12):5553. doi:10.3390/ijms27125553
BibTeX
@article{Ramos2026,
author = {Ramos, Hugo and Simó-Servat, Olga and Hernández, Cristina and Simó, Rafael},
title = {Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5553},
doi = {10.3390/ijms27125553}
}
EUVIMED